Breakpoints
by Society of Infectious Diseases Pharmacists
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇮🇳IN · Health & Fitness#1761K to 10K
- 🇻🇳VN · Health & Fitness#193500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
750 to 6.5K🎙 ~2x weekly·133 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
1.5K to 13K🇮🇳77%🇻🇳23% - Active Followers
Loyal subscribers who consistently listen
450 to 3.9K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 15 epsHosts
Recent guests
Recent episodes
#138 – You CAN Go Home Again: A review of OPAT and CoPAT from the MAD-ID/SIDP Annual Meeting
Jul 3, 2026
1h 14m 53s
#137 – Hot Topics: What You May Have Missed in Infectious Diseases 2025-2026 (LIVE from MAD-ID)
Jun 19, 2026
1h 08m 59s
#136 – GAS, Streptococcus pyogenes: Call It What You Want, It’s Got a Big Reputation
Jun 5, 2026
1h 25m 11s
#135 – Stewie Struggles: Small Hospital Edition
May 22, 2026
1h 02m 43s
#134 – ESCMID Global Trials: PETER PEN and ASTARTE
May 8, 2026
1h 03m 15s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/3/26 | outpatient parenteral antimicrobial therapycomplex outpatient antimicrobial therapy+3 | Dr. Monica MahoneyDr. Mark Gilchrist | MAD-IDSIDP+2 | — | OPATCoPAT+4 | — | 1h 14m 53s | ||
| 6/19/26 | infectious diseasestrials+3 | Dr. Megan Klatt | Society of Infectious Diseases PharmacistsBCIDP+1 | — | infectious diseasestrials+5 | — | 1h 08m 59s | ||
| 6/5/26 | Group A Streptococcusvaccine development+4 | Dr. Shiranee SriskandanDr. Josh Osowicki+1 | Society of Infectious Diseases PharmacistsJAMA+2 | — | Group A Streptococcuspharyngitis+5 | — | 1h 25m 11s | ||
| 5/22/26 | antimicrobial stewardshipsmall hospitals+4 | Dr. Tina KhademDr. Ashley Cubillos | Society of Infectious Diseases PharmacistsImplementation of Core Elements at Small and Critical Access Hospitals+3 | — | antimicrobial stewardshipsmall hospitals+5 | — | 1h 02m 43s | ||
| 5/8/26 | clinical trialscephalosporin-resistant Enterobacterales+4 | Mical PaulJesús Rodríguez-Baño | ESCMIDPiperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)+1 | — | clinical trialsbacteremia+6 | — | 1h 03m 15s | ||
| 4/17/26 | climate changehealthcare sustainability+4 | Shreya DoshiAndrea Pallotta+1 | Sustainabil‑IDNational Academy of Medicine+10 | — | climate changehealthcare+5 | — | 48m 05s | ||
| 3/13/26 | Complicated UTIsAntimicrobial decisions+3 | Dr. Dana BowersKyle Molina | Society of Infectious Diseases PharmacistsGuidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement+3 | — | complicated UTIsantimicrobial decisions+3 | — | 1h 08m 33s | ||
| 2/22/26 | guidelineshealthcare+4 | Pranita TammaBenedikt Huttner | Society of Infectious Diseases PharmacistsWHO+4 | — | guidelineshealthcare+4 | — | 1h 00m 17s | ||
| 1/30/26 | amoxicillinpediatric patients+3 | Dr. Ted MortonDr. Christine Lockowitz | Society of Infectious Diseases PharmacistsPediatr Infect Dis J+3 | — | amoxicillinpediatric dosing+3 | — | 1h 00m 17s | ||
| 1/16/26 | fungal infectionsepidemiology+3 | Dr. Gregory EschenauerDr. George R Thompson | BlastomycesHistoplasma+2 | — | fungal infectionsBlastomyces+6 | — | 1h 22m 58s | ||
| 12/19/25 | IDWeek 2025clinical trials+3 | — | Society of Infectious Diseases Pharmacists | — | IDWeek 2025clinical trials+3 | — | 1h 35m 54s | ||
| 11/28/25 | pneumoniaantimicrobial guidelines+3 | Dr. Whitney Hartlage | Infectious Diseases Society of AmericaAm J Respir Crit Care Med+1 | — | pneumoniaATS guidelines+3 | — | 52m 27s | ||
| 11/14/25 | gut microbiomeC. difficile infections+3 | Dr. Krista GensDr. Javier A. Villafuerte Gálvez | OpenBiomeFDA+1 | — | microbiomeC. difficile+3 | Nestlé Health Science | 1h 08m 15s | ||
| 10/31/25 | antimicrobial resistanceopportunistic pathogens+5 | Dr. Maria MojicaDr. Robert Bonomo+1 | An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative BacteriaCharacterization of a Novel Pathogen in Immunocompromised Patients: Elizabethkingia anophelis -Exploring the Scope of Resistance to Contemporary Antimicrobial Agents and β-lactamase Inhibitors | — | BurkholderiaAchromobacter+5 | Shionogi Inc. | 1h 32m 54s | ||
| 10/10/25 | cefepime dosingrenal impairment+3 | Dr. Erin BarretoDr. Jeffrey Lipman | Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy+3 | — | cefepimedosing consult+3 | — | 1h 16m 08s |
Showing 15 of 15
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Breakpoints
Peaked at #176 in India, currently #176 in India.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| India | — | #176 | #176 | — |
| VN | — | #193 | #193 | — |
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.